Novartis, Shire Among Interested Buyers for ThromboGenics

Novartis AG and Shire Plc are among drugmakers weighing offers for Belgian eye-medicine company ThromboGenics NV, people familiar with the matter said. Novartis is considered the most likely buyer because it already has a partnership to market ThromboGenics’s Jetrea eye medicine outside of the U.S. The sale may value the company at as much as $1.3 billion, according to sources. Read the full story

More News:

All news »

What are your comments?

You cannot post comments until you have logged in. Login Here.

Comments

No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments